606 related articles for article (PubMed ID: 20816021)
21. Beta-cell function and mass in type 2 diabetes.
Larsen MO
Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
23. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
Rachman J; Barrow BA; Levy JC; Turner RC
Diabetologia; 1997 Feb; 40(2):205-11. PubMed ID: 9049482
[TBL] [Abstract][Full Text] [Related]
24. Islet cell function: alpha and beta cells--partners towards normoglycaemia.
Göke B
Int J Clin Pract Suppl; 2008 Mar; (159):2-7. PubMed ID: 18269435
[TBL] [Abstract][Full Text] [Related]
25. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
Henkel E; Menschikowski M; Koehler C; Leonhardt W; Hanefeld M
Metabolism; 2005 Sep; 54(9):1168-73. PubMed ID: 16125528
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
27. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH
Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
[TBL] [Abstract][Full Text] [Related]
28. Incretin hormones and beta cell function in chronic pancreatitis.
Knop FK
Dan Med Bull; 2010 Jul; 57(7):B4163. PubMed ID: 20591345
[TBL] [Abstract][Full Text] [Related]
29. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
Meier JJ; Gallwitz B; Salmen S; Goetze O; Holst JJ; Schmidt WE; Nauck MA
J Clin Endocrinol Metab; 2003 Jun; 88(6):2719-25. PubMed ID: 12788879
[TBL] [Abstract][Full Text] [Related]
30. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.
Hare KJ; Vilsbøll T; Asmar M; Deacon CF; Knop FK; Holst JJ
Diabetes; 2010 Jul; 59(7):1765-70. PubMed ID: 20150286
[TBL] [Abstract][Full Text] [Related]
31. Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects.
Bagger JI; Grøndahl MFG; Lund A; Holst JJ; Vilsbøll T; Knop FK
Diabetes; 2021 Jun; 70(6):1347-1356. PubMed ID: 33722838
[TBL] [Abstract][Full Text] [Related]
32. [The changes of gastrointestinal hormones GLP-1, PYY and ghrelin in patients with newly diagnosed type 2 diabetes mellitus].
Cui T; Ren Y; Ma H; Liu SF; Zhang XX; Yu HL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 44(5):774-8. PubMed ID: 24325110
[TBL] [Abstract][Full Text] [Related]
33. Altered Plasma Levels of Glucagon, GLP-1 and Glicentin During OGTT in Adolescents With Obesity and Type 2 Diabetes.
Manell H; Staaf J; Manukyan L; Kristinsson H; Cen J; Stenlid R; Ciba I; Forslund A; Bergsten P
J Clin Endocrinol Metab; 2016 Mar; 101(3):1181-9. PubMed ID: 26745255
[TBL] [Abstract][Full Text] [Related]
34. The spectrum of antidiabetic actions of GLP-1 in patients with diabetes.
Vilsbøll T; Holst JJ; Knop FK
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):453-62. PubMed ID: 19748063
[TBL] [Abstract][Full Text] [Related]
35. Incretin and glucagon levels in adult offspring exposed to maternal diabetes in pregnancy.
Kelstrup L; Clausen TD; Mathiesen ER; Hansen T; Holst JJ; Damm P
J Clin Endocrinol Metab; 2015 May; 100(5):1967-75. PubMed ID: 25781355
[TBL] [Abstract][Full Text] [Related]
36. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.
Knop FK; Vilsbøll T; Madsbad S; Holst JJ; Krarup T
Diabetologia; 2007 Apr; 50(4):797-805. PubMed ID: 17225124
[TBL] [Abstract][Full Text] [Related]
37. Elevated glucagon-like peptide-1 plasma levels, as a possible adaptive response, in diabetic NOD mice.
Rydgren T; Börjesson A; Carlsson A; Sandler S
Biochem Biophys Res Commun; 2012 Jul; 423(3):583-7. PubMed ID: 22695119
[TBL] [Abstract][Full Text] [Related]
38. Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients.
Kielgast U; Asmar M; Madsbad S; Holst JJ
J Clin Endocrinol Metab; 2010 May; 95(5):2492-6. PubMed ID: 20207828
[TBL] [Abstract][Full Text] [Related]
39. Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.
Becker RH; Stechl J; Msihid J; Kapitza C
Diabetes Obes Metab; 2014 Sep; 16(9):793-800. PubMed ID: 24521245
[TBL] [Abstract][Full Text] [Related]
40. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.
Zander M; Madsbad S; Madsen JL; Holst JJ
Lancet; 2002 Mar; 359(9309):824-30. PubMed ID: 11897280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
